Get the latest delivered to your inbox
Privacy Policy

Now Reading

Novo Nordisk to Reach 2500 Children in India with Free Insulin and Diabetes Care

Novo Nordisk to Reach 2500 Children in India with Free Insulin and Diabetes Care

Published 09-09-11

Submitted by Novo Nordisk

With more than 50 million people living with diabetes in India and only scarce data existing about children with diabetes, Novo Nordisk today launched the Changing Diabetes® in Children (CDiC) programme in the country. The programme is a partnership initiative that works to improve the provision of childhood diabetes care in developing countries.

There are many barriers to diabetes care for children living with the disease in developing countries. Among these is lack of trained healthcare professionals, lack of healthcare infrastructure and dilemmas for families having to choose between food and life-saving medicine. Such circumstances may lead to misdiagnosis, poor management of treatment, early complications and premature death of children.

The programme entails free provision of insulin, blood glucometers and strips for the children and  a comprehensive training manual for healthcare professionals and diabetes educators has been developed as well as locally adapted educational materials for children and their families.

In India, 12 key opinion leaders have been attached to run 12 CDiC clinics covering a total of 10 Indian states. This makes the Indian launch of the CDiC programme the most extensive engagement yet.

By the end of the project in 2015, a sustainable cooperation with local partners, including governments and diabetes associations, entailing well-functioning diabetes clinics, should be in place.

The programme is now active in eight countries (Bangladesh, Cameroon, Democratic Republic of Congo, Ethiopia, India, Guinea, Tanzania and Uganda) and will be rolled out to Kenya within the next few months. The ambition is to reach and provide care to 10,000 children by 2015. Currently there are over 1,600 children enrolled and 16 clinics have been established. To read more about the Changing Diabetes in Children programme and our collaborating partners, click here.

Novo Nordisk logo

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk

Join today and get the latest delivered to your inbox